Frontiers in Bioscience-Landmark (Oct 2023)

A Pharmaceutical Paradigm for Cardiovascular Composite Risk Assessment Using Novel Radiogenomics Risk Predictors in Precision Explainable Artificial Intelligence Framework: Clinical Trial Tool

  • Luca Saba,
  • Mahesh Maindarkar,
  • Narendra N. Khanna,
  • Amer M. Johri,
  • Laura Mantella,
  • John R. Laird,
  • Kosmas I. Paraskevas,
  • Zoltan Ruzsa,
  • Manudeep K. Kalra,
  • Jose Fernandes E. Fernandes,
  • Seemant Chaturvedi,
  • Andrew Nicolaides,
  • Vijay Rathore,
  • Narpinder Singh,
  • Mostafa M. Fouda,
  • Esma R. Isenovic,
  • Mustafa Al-Maini,
  • Vijay Viswanathan,
  • Jasjit S. Suri

DOI
https://doi.org/10.31083/j.fbl2810248
Journal volume & issue
Vol. 28, no. 10
p. 248

Abstract

Read online

Background: Cardiovascular disease (CVD) is challenging to diagnose and treat since symptoms appear late during the progression of atherosclerosis. Conventional risk factors alone are not always sufficient to properly categorize at-risk patients, and clinical risk scores are inadequate in predicting cardiac events. Integrating genomic-based biomarkers (GBBM) found in plasma/serum samples with novel non-invasive radiomics-based biomarkers (RBBM) such as plaque area, plaque burden, and maximum plaque height can improve composite CVD risk prediction in the pharmaceutical paradigm. These biomarkers consider several pathways involved in the pathophysiology of atherosclerosis disease leading to CVD. Objective: This review proposes two hypotheses: (i) The composite biomarkers are strongly correlated and can be used to detect the severity of CVD/Stroke precisely, and (ii) an explainable artificial intelligence (XAI)-based composite risk CVD/Stroke model with survival analysis using deep learning (DL) can predict in preventive, precision, and personalized (aiP3) framework benefiting the pharmaceutical paradigm. Method: The PRISMA search technique resulted in 214 studies assessing composite biomarkers using radiogenomics for CVD/Stroke. The study presents a XAI model using AtheroEdgeTM 4.0 to determine the risk of CVD/Stroke in the pharmaceutical framework using the radiogenomics biomarkers. Conclusions: Our observations suggest that the composite CVD risk biomarkers using radiogenomics provide a new dimension to CVD/Stroke risk assessment. The proposed review suggests a unique, unbiased, and XAI model based on AtheroEdgeTM 4.0 that can predict the composite risk of CVD/Stroke using radiogenomics in the pharmaceutical paradigm.

Keywords